Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis

Deep Chandh Raja^{1,2,3,4}, Indira Samarawickrema^{4,2}, Souvik Das^{3,4}, Abhinav Mehta¹, Lukah Tuan^{1,4}, Sanjiv Jain², Sanjay Dixit⁵, Frank Marchlinski⁵, Walter P. Abhayaratna^{1,3}, Prashanthan Sanders⁶ and Rajeev K Pathak^{1,2,3,4*}

¹Australian National University, Canberra, Australian Capital Territory, Australia; ²University of Canberra, Canberra, Australian Capital Territory, Australia; ³Canberra Health Services, Canberra, Australian Capital Territory, Australia; ⁴Canberra Heart Rhythm Centre, Canberra, Australian Capital Territory, Australia; ⁵Electrophysiology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; and ⁶Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia

Abstract

Aims Heart failure patients with mid-range ejection fraction (HFmrEF) have overlapping clinical features, compared with patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). We aim to perform a meta-analysis of studies reporting long-term outcomes in HFmrEF compared with HFrEF and HFpEF.

Methods and results Data from 18 eligible large-scale studies including 126 239 patients were pooled. Patients with HFmrEF had a lower risk of all-cause death than those with HFrEF [risk ratio (RR) = 0.92; 95% CI = 0.85–0.98; P < 0.001]. This significant difference was seen in the follow-up at 1, 2, and 3 years. Patients with HFmrEF had significantly lower risk of cardiovascular (CV) deaths than HFrEF (RR = 0.77; 95% CI = 0.65–0.92; P < 0.001). Subgroup analysis showed that studies recruiting >50% of males had higher risk of deaths with HFrEF (RR = 1.15; 95% CI = 1.04–1.26; P = 0.006). When compared with HFpEF, patients with HFmrEF had comparable risk of all-cause death (RR = 1.02; 95% CI = 0.96–1.09; P = 0.53). Similarly, there were no differences in the 1, 2, and 3 year deaths; CV and non-CV deaths were insignificant between HFmrEF and HFpEF.

Conclusions The results of the study support that HFmrEF has better prognosis than HFrEF but similar prognosis when compared with HFpEF. Gender disparity between studies seems to influence the results between HFmrEF and HFrEF. Transition in left ventricular ejection fraction (LVEF), which could not be addressed in the study, may play a decisive role in determining outcomes. PROSPERO review registration number CRD42021277107.

Keywords Systematic review; Meta-analysis; Heart failure; Mid-range ejection fraction; Mortality; Gender differences

Received: 1 April 2022; Revised: 9 July 2022; Accepted: 15 August 2022

*Correspondence to: Rajeev K Pathak, Cardiac Electrophysiology Unit, Department of Cardiology, Canberra Hospital, Australian National University, Yamba Drive, Garran, ACT 2605, Australia. Email: rajeev.pathak@canberraheartrhythm.com.au

Funding information: The authors declare there is no source of funding.

[Correction added on 06 September 2022, after first online publication: The first author's name has been corrected in this version.]

Introduction

Mortality in patients with symptomatic chronic heart failure varies from 25% to 80% at 5 years, depending on the stage of heart failure.¹ Left ventricular ejection fraction (LVEF) is an important prognostic indicator for the risk of all-cause mortality as well as sudden cardiac death in chronic heart failure patients.² Since the introduction of categories of chronic heart failure based on LVEF, heart failure with mid-range (borderline) ejection fraction (HFmrEF) is recognized as an entity with overlapping clinical, treatment, and

outcome characteristics compared with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).³

Large-scale registries, multi-centre, and single-centre studies have reported their observations on prognosis in each of these categories of heart failure.^{4–21} However, only a few meta-analyses have been carried out comparing the prognosis of HFmrEF with HFrEF and HFpEF.^{22–24} Moreover, these meta-analyses did not then have studies adequately powered to examine the annual mortality risk in the follow-up between these groups. Additionally, none of the meta-analyses have

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. explored the difference in outcomes according to certain important subgroups, which could be important moderators influencing the results. To explore these gaps in knowledge, we proposed a systematic review and meta-analysis to determine the long-term cumulative and annual mortality risk, cardiovascular and non-cardiovascular deaths in patients with HFmrEF compared with those with HFrEF and HFpEF.

Methods

Objectives

The primary objective was to determine the effect size of long-term cumulative mortality risk and all-cause mortality risk at 1, 2, 3, 4, 5, and 10 years; in persons with HFmrEF compared with HFrEF and HFpEF. Our secondary objectives were to (1) explore the long-term cause-specific mortality risk for deaths from cardiovascular, non-cardiovascular, heart failure, and sudden cardiac deaths in persons with HFmrEF compared with HFrEF and HFpEF and (2) identify clinical variables influencing the long-term mortality risk estimates.

Search strategy and eligibility criteria

We followed the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines in conducting this systematic review and the meta-analysis.²⁵ We searched MEDLINE, PubMed, EMBASE, Web of Science, and Cochrane Library from inception to 30 September 2021, for studies reporting mortality outcomes between persons with heart failure with mid-range/borderline ejection fraction (40%–49%, HFmrEF) compared with reduced (<40%, HFrEF) or preserved ejection fraction (\geq 50%, HFpEF). The key search terms used were 'ejection-fraction', 'heart-failure', 'death*', 'mortality*', and 'hazard-ratio*'. The detailed search strategy is in Supporting Information, *Table S1*. To identify additional studies, we manually searched the reference lists of the included studies. This study is registered at the PROSPERO review database (CRD42021277107).

The inclusion criteria were full-text peer reviewed papers in English, randomized controlled trials, cohort studies, observational studies with consecutive recruitment of patients with heart failure; standard case definition of heart failure, studies defining HFmrEF or borderline heart failure ejection fraction as 40%–49%, HFrEF as <40%, and HFpEF as \geq 50% in adults aged 18 years and above; reporting cumulative all-cause deaths in HFmrEF and HFrEF/HFpEF/both along with annual all-cause, cardiovascular, non-cardiovascular, heart failure deaths or sudden cardiac deaths; follow-up \geq 1 year; the sample size \geq 100 with HFmrEF and the total sample size of heart failure patients \geq 1000 when the power of the study was not listed. When there were \geq 2 articles on the same group of patients, we selected the newest study best representing the cohort and the inclusion criteria.

The exclusion criteria were study protocols, brief reports, case studies, abstracts, theses, reviews, duplicate studies, incomplete and unpublished studies, studies of pregnant women, participants with a specific disease or a health condition in addition to heart failure and duplicate studies reporting outcomes from the same study population.

Data extraction

Retrieved studies were exported to Covidence^R. I. S. (Indira Samarawickrema) and D. R. (Deep Raja) screened the titles and the abstracts independently in Covidence^R for eligibility. R. P. (Rajeev Pathak) was the third independent reviewer. I. S. and D. R. independently extracted data from the eligible full-text studies into the custom designed data extraction tables in Covidence^R. Corresponding authors of studies without data on mortality outcomes were contacted. We analysed for consensus to ensure reliability of the data. Inter-rater agreement in data extraction was calculated. We had meetings to come to a consensus to resolve any discrepancies.

The data collated comprised study design, dataset, study period, study population, definitions of mid-range or borderline, reduced and preserved ejection fraction in heart failure, mean follow-up and standard deviation, study power, sample size, mean age and standard deviation, proportion of males, number of patients at baseline, number of cumulative, cardiovascular, non-cardiovascular and sudden cardiac deaths and all-cause deaths at 1 year intervals up to 10 years.

Quality appraisal

I. S. and D. R. independently assessed the quality of eligible used Newcastle-Ottawa quality assessment scale (NOS) for cohort studies and Cochrane Risk of Bias tool for randomized clinical trials (RoB 2).²⁵ We calculated inter-rater agreement for quality assessment and consensus reached following discussions for the disagreements. The third independent reviewer was R. P. The objective of the quality appraisal was to exclude low quality studies, that is, NOS score <7 and RoB 2 score <2. This study did not have patient or public involvement.

Statistical analysis

Pooled data of mortality and survival data for HFmrEF were compared with HFrEF and HFpEF for cumulative, cardiovascular, non-cardiovascular, heart failure and sudden cardiac deaths; and cumulative deaths at 1, 2, 3, 4, 5, and 10 years; to determine the effect size [risk ratio (RR)] for the risk of death in the meta-analysis. To minimize potential of biases,

each meta-analysis required ≥ 2 studies. Heterogeneity was calculated as l^2 , and the cut-off for low heterogeneity was $l^2 < 30\%$. We used random effects maximum likelihood model for $l^2 \geq 30\%$ and fixed effect model with inverse-variance for $l^2 < 30\%$. We reported exponentiated effect sizes from the log risk ratios. The effect size for death was determined as a risk ratio with 95% confidence intervals in the meta-analysis.

We explored heterogeneity between studies due to publication bias with visual inspection of funnel plots and Egger's linear regression test for the influence from small studies. Sensitivity analysis excluding one study at a time was also performed to examine the influence of individual study on the effect size. We examined potential factors for between-study heterogeneity with clinically and epidemiologically relevant covariates (moderators) in the subgroup analysis and in the random-effects meta-regression. The covariates included were the proportion of men below or above 50%, mean age of the participants below or above 50 years, studies recruiting outpatients versus hospitalized patients, studies recruiting de novo versus chronic heart failure patients, single versus multi-centre studies, and follow-up period ≤ 2 versus > 2 years. We conducted statistical analyses with Stata 17.0 (STATA Corporation, Texas, USA).

Results

The search process is outlined in *Figure 1*, and the search strategy is listed in Supporting Information, *Table S1*. Eighteen eligible studies were included in the meta-analysis of the mortality outcomes between HFmrEF and HFrEF, and 17 eligible studies were included in meta-analysis of the mortality outcomes between HFmrEF and HFpEF. All studies were follow-up of patient cohorts from observational studies and there were no eligible randomized controlled trials. Inter-rater reliability in data extraction was 0.91, and Cohen's kappa was 0.39. The quality of evidence of each selected study is listed in Supporting Information, *Table S2*. Inter-rater reliability in quality appraisal was 0.84, and Cohen's kappa was 0.67.

Figure 1 Flow chart of search process and results



Study and patient characteristics

There were 14 prospective and 4 retrospective cohort studies; 13 including hospitalized patients; 3 including outpatients; 14 multi-centre and 4 single-centre studies; 13 studies with enrolments before 2010; and 5 studies with enrolments during or after 2010 (*Table 1*). The participant follow-up ranged from 1 to 10 years. The noteworthy large-scale studies were the 1 and 5 year data from the Get With The Guidelines–Heart failure (GWTG-HF) registry, 3 year data from the Swedish Heart Failure Registry, and 1 year data from the ESC Heart Failure long-term registry.^{5,8,15,19} Choi *et al.* reported outcomes for both de novo heart failure and acute decompensated chronic heart failure patients and was hence considered as two separate studies.⁹

The included studies had 126 239 heart failure patients inclusive of; 64 779 patients with HFrEF (51.3%); 20 301 patients with HFmrEF (16.1%); and 41 159 patients with HFpEF (32.6%). The average age of the patients was 71.9 years. The proportion of men in the overall cohort was 60.6% with 60.5% in HFrEF, 69% in HFmrEF and 40.4% in HFpEF. The HFmrEF group had significantly reduced proportion of patients with hypertension, diabetes mellitus, kidney disease, atrial fibrillation, and coronary artery disease (9.7%, 5.2%, 3.2%, 7%, 8.1% respectively) than both HFrEF (29%, 17%, 11%, 19%, 27% respectively) and HFpEF groups (23%, 11%, 8.5%, 14.6%, 12.2% respectively) (Supporting Information, *Table S3*).

Risk of all-cause mortality

Patients with HFmrEF had a significantly lower risk of all-cause death than those with HFrEF (Risk Ratio (RR) = 0.92; 95% CI = 0.85–0.98; P < 0.001), using the random-effects model (Figure 2). Subgroup analysis (Figure 3) revealed that studies recruiting >50% of men had a lower risk ratio for HFmrEF versus HFrEF (RR = 0.87; 95% CI = 0.79-0.96; P = 0.006). This translated into a higher risk of deaths with HFrEF in studies recruiting >50% of males (RR = 1.15; 95% CI = 1.04-1.26; P = 0.006). However, studies ≤50% of men had insignificant differences in the risks of deaths (HFmrEF vs. HFrEF: RR = 1.00; 95% CI = 0.99-1.03; P = 0.63). Subgroup analysis also revealed that studies including only outpatients had lesser risk of death with HFmrEF (RR = 0.78; 95% CI = 0.65-0.93; P = 0.006) than studies including only hospitalized patients (RR = 0.97; 95% CI = 0.94-1.01; P = 0.13).

Patients with HFmrEF had comparable risk of all-cause death with HFpEF (pooled RR = 1.02; 95% CI = 0.96–1.09; P = 0.53) using the random-effects model (*Figure 2*). Subgroup analysis (*Figure 3*) revealed higher risk of deaths in HFmrEF, than HFpEF, in single-centre studies (RR = 1.13;

95% CI = 1.03–1.24; *P* = 0.008) compared with multi-centre studies (RR = 1.00; 95% CI = 0.92–1.07; *P* = 0.91).

There was high level of heterogeneity between the included studies for HFmrEF versus HFrEF ($I^2 = 87\%$) as well as for HFmrEF versus HFpEF ($I^2 = 80.2\%$). To assess publication bias, a sensitivity analysis was conducted by exclusion of individual studies and the smaller studies, and this was found to not affect the results. Meta-regression analysis for between-study variance in overall mortality risk ratio between HFmrEF and HFrEF identified that studies on hospitalized patients and multi-centre studies contributed to 98.6% variance (P = 0.0001). Meta-regression analysis for between-study variance in overall mortality risk ratio between HFmrEF and HFpEF identified that multi-centre studies attribute to 53.7% of variance (P = 0.005).

Annual all-cause mortality in the follow-up

Analysis of studies with annual all-cause deaths showed that patients with HFmrEF had a significantly lower risk of all-cause death than those with HFrEF at 1 year (7 studies; pooled RR = 0.84; 95% CI = 0.74–0.95; P = 0.03; $l^2 = 54\%$), 2 years (4 studies; pooled RR = 0.86; 95% CI = 0.75–0.98; $l^2 = 34\%$), and 3 years (2 studies; pooled RR = 0.38; 95% CI = 0.32–0.44; $l^2 = 88\%$) (*Figure 3*). The differences were insignificant at 5 years (4 studies) and 10 years (2 studies). In contrast, patients with HFmrEF had comparable risk of all-cause death with HFpEF at all the specified years (*Figure 4*).

Cardiovascular, non-cardiovascular deaths, heart failure, and sudden cardiac deaths

Patients with HFmrEF had significantly lower risk of cardiovascular deaths than HFrEF (pooled RR = 0.77; 95% CI = 0.65–0.92; P < 0.001; l^2 = 76%) (*Figure 4*, Supporting Information, *Figures S1–S3*). Patients with HFmrEF had significantly lower risk of SCD than in HFrEF (pooled RR = 0.59; 95% CI = 0.41–0.85; P < 0.001; l^2 = 0). Patients with HFmrEF had trends of lower risk of heart failure related deaths than in HFrEF (pooled RR = 0.72; 95% CI = 0.43–1.21; P = 0.21; l^2 = 86%). However, the risk of non-cardiovascular deaths was comparable (pooled RR = 1.20; 95% CI = 1.05–1.37; P = 0.15; l^2 = 12.7%) between HFmrEF and HFrEF groups.

In contrast, patients with HFmrEF and HFpEF had comparable risks of cardiovascular deaths (pooled RR = 1.10; 95% CI = 0.99–1.21; P = 0.38; $I^2 = 6\%$), heart failure deaths (pooled RR = 0.93; 95% CI = 0.70–1.24; P = 0.62; $I^2 = 44\%$), SCD (pooled RR = 1.33; 95% CI = 0.85–2.09; P = 0.27; $I^2 = 23\%$), and non-cardiovascular deaths (pooled RR = 1.05; 95% CI = 0.77–1.44; P = 0.76; $I^2 = 77\%$) (*Figure 5*).

							Number	of patient	S			
				Follow-	Age ^b (years) (mean + SD/	Total	HFrEF (<	40%)	HFmrEF (4	0%–49%)	HFpEF (25	(%0
Source ^a	Study design	Country	Study period	years	median ± IQR)	size	No.	Male %	No.	Male %	No.	Male %
Bonsu <i>et al.</i> , 2017	Retrospective single hospital registry	Ghana	January 2009 to December 2013	ъ	60.8 ± 14.6	1488	345	48.1	265	50.2	878	43.3
Cheng <i>et al</i> ., 2014	Prospective multi-hospital registry	USA	January 2005 to December 2011		80 ± 74-86	40 239	15 716	60	5626	49.5	18 897	32.7
Chioncel et <i>al.</i> , 2017	Prospective multi-hospital registry	Europe and Mediterranean	May 2011 to April 2013	-	68.6 ± 13.7	9134	5460	78.4	2212	68.5	1462	52.1
Choi et al.,	Prospective	South Korea	March 2011 to	4	71.7 ± 14.5	2867	1631	61.8	492	50	744	42.3
2018 de novo Choi et <i>al.</i> ,	multi-hospital registry Prospective	South Korea	February 2014 March 2011 to	4	72.6 ± 12.0	2547	1551	60.7	383	43.9	613	33.8
2018 ADHF Coles <i>et al.</i> , 2014 ⁺	multi-hospital registry Prospective	USA	February 2014 1995, 2000,	4	76.5 ± 11.9	3604	1479	56.5	346	45.4	1779	33.4
Farre <i>et al.</i> , 2017	multi-nospital registry Prospective	Spain	ZUUZ, ZUU4 Aug 2001 to	10	73.5 ± 11.4	3580	2232	75.7	504	66.9	844	44
Ganapathi	Retrospective single	India	January 2001 to	10	48.8 ± 14.7	1502	404	78.2	231	74.5	867	51.7
Gomez-Otero	Prospective	Spain	October 2013 to	-	72.5 ± 11.1	1420	583	76.7	227	67	610	46.7
er al., 2017 Guisado-Espartero	multi-nospital registry Prospective	Spain	December 2014 February 2008 to	-	81 ± 76–86	2753	808	62.5	281	58	1664	37.4
<i>et al.</i> , 2018 Hamatani	multi-hospital registry Prospective	Japan	February 2009 June 2005 to	D.	77 ± 11	1792	860	71.2	318	64.5	614	47.4
<i>et al.</i> , 2018 Koh <i>et al.</i> , 2017	multi-hospital registry Retrospective	Sweden	April 2016 January 2000 to	m	77 ± 11	42 061	23 402	71.2	9019	60.8	9640	45.4
Lam <i>et al.</i> , 2018	multi-hospital registry Prospective	New Zealand,	December 2012 March 2010 to	2	71.5 ± 11.8	2039	1209	83.5	256	69.9	574	52.3
Liu e <i>t al.</i> , 2021 ⁺	multi-hospital registry Retrospective single	Singapore Germany	August 2014 July 2009 to	∞	69 ± 13	2018	1067	76.3	951	74.2	1	I
Pascual-Figal	hospital registry Prospective	Spain	December 2017 April 2003 to	4	72.1 ± 12.2	3446	2351	76.8	460	73	635	42.8
et <i>al., 2</i> 017 Shah et <i>al.,</i> 2017	multi-hospital registry Prospective	USA	January 2011 January 2005 to	Ŋ	82 ± 75-87	39 982	18 398	59	3285	48.5	18 299	32.4
Shiga <i>et al.</i> , 2019	multi-nospital registry Retrospective multi-hospital registry	Japan	30 December 2009 April 2013 to	2	81 ± 72–87	1156	412	68.2	248	53.2	496	39.5
Vergaro et <i>al.</i> , 2019 ⁺	Prospective single hospital registry	Italy	January 2000 to December 2016	Ŋ	71 ± 12	2791	1539	76.3	623	71.6	629	4.5
Abbreviations: ADH heart failure with p "Studies have been HFmEF as 40%–49 bAverage age is pres	F, acute decompensated reserved ejection fraction mentioned in order of fii %.	l heart failure pat r rst author followe standard deviati	cients; HFrEF, heart fai ed by year of publicati ion or median with 25	lure with on; additi th and 75	reduced ejection onally, these stuc th interquartile r	fraction; H lies had d anges.	HFmrEF, he efined HFr	eart failur mrEF as 41	e with mid- %–49%, re	range ejectio :mainder of tl	n fraction; he studies	HFpEF, defined

Table 1 Characteristics of the included studies

ESC Heart Failure 2022; **9**: 4088–4099 DOI: 10.1002/ehf2.14125 Figure 2 Forest plots demonstrating all-cause deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF. HFmrEF, heart failure with mid-range (borderline) ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

(A)	HFr	nrEF	HF	rEF		Risk ratio	Weight
Study	Died	No	Died	No		with 95% CI	(%)
Coles 2014	241	105	1,052	427		0.98 [0.91, 1.06]	7.63
Bonsu 2017	89	176	119	226		0.97 [0.78, 1.22]	4.55
Chioncel 2017	168	2,044	480	4,980	- B +	0.86 [0.73, 1.02]	5.66
Farre 2017	221	283	1,023	1,209		0.96 [0.86, 1.07]	6.99
Gomez-Otero 2017	55	172	116	467		- 1.22 [0.92, 1.61]	3.57
Koh 2017	2,512	6,507	6,706	16,696	D	0.97 [0.93, 1.01]	8.18
Pascual-Figal 2017	128	332	776	1,575		0.84 [0.72, 0.99]	5.89
Shah 2017	2,487	798	13,847	4,551		1.01 [0.98, 1.03]	8.33
Bhambhani 2018	63	137	312	736		1.06 [0.85, 1.32]	4.52
Choi 2018 de novo	147	345	438	1,193		1.11 [0.95, 1.30]	5.91
Choi 2018 ADHF	171	212	694	857		1.00 [0.88, 1.13]	6.65
Hamatani 2018	60	258	178	682		0.91 [0.70, 1.19]	3.86
Guisado-Espartero 2018	56	225	226	582	-8	0.71 [0.55, 0.92]	3.92
Lam 2018	30	226	233	976		0.61 [0.43, 0.87]	2.67
Shiga 2019	40	208	73	339		0.91 [0.64, 1.29]	2.70
Vergaro 2019	166	457	631	908		0.65 [0.56, 0.75]	6.22
Ganapathi 2020	136	95	254	150		0.94 [0.82, 1.07]	6.49
Liu 2021	237	714	329	738	-8-	0.81 [0.70, 0.93]	6.25
Overall						0.92 [0.85, 0.98]	
Heterogeneity: $\tau^2 = 0.02$, I^2	= 87.69	9%, H ² =	8.12				
Test of $\theta_i = \theta_j$: Q(17) = 69.3	33, <i>P</i> = 0	0.00		-			

Test of $\theta = 0$: z = -2.44, P = 0.01 \leftarrow Less deaths in HFmrEF ¹ More deaths in HFmrEF \rightarrow Random effects REML model

(B)	HFn	nrEF	HFp	EF		Risk ratio	Weight
Study	Died	No	Died	No		with 95% CI	(%)
Coles 2014	241	105	1,222	557		1.01 [0.94, 1.09]	9.44
Bonsu 2017	89	176	264	614		1.12 [0.92, 1.36]	5.38
Chioncel 2017	168	2,044	92	1,370		1.21 [0.94, 1.54]	4.21
Farre 2017	221	283	444	400		0.83 [0.74, 0.94]	7.98
Gomez-Otero 2017	55	172	118	492		- 1.25 [0.95, 1.66]	3.53
Koh 2017	2,512	6,507	3,180	6,460		0.84 [0.81, 0.88]	10.37
Pascual-Figal 2017	128	332	178	457		0.99 [0.82, 1.20]	5.50
Shah 2017	2,487	798	13,843	4,456	<u> </u>	1.00 [0.98, 1.02]	10.77
Bhambhani 2018	63	137	231	580		1.11 [0.88, 1.39]	4.51
Choi 2018 de novo	147	345	206	538		1.08 [0.90, 1.29]	5.93
Choi 2018 ADHF	171	212	245	368		1.12 [0.96, 1.30]	6.91
Hamatani 2018	60	258	106	508		1.09 [0.82, 1.46]	3.45
Guisado-Espartero 2018	56	225	366	1,298		0.91 [0.70, 1.16]	4.09
Lam 2018	30	226	80	494		0.84 [0.57, 1.25]	2.15
Shiga 2019	40	208	79	417		1.01 [0.71, 1.43]	2.59
Vergaro 2019	166	457	144	485		1.16 [0.96, 1.41]	5.48
Ganapathi 2020	136	95	453	414		1.13 [0.99, 1.28]	7.71
Overall					+	1.02 [0.96, 1.09]	
Heterogeneity: $\tau^2 = 0.01$, l	2 = 80.23	3%, H ² =	5.06				
Test of $\theta_i = \theta_j$: Q(16) = 78.3	37, <i>P</i> = 0	.00			1		
Test of θ = 0: z = 0.63, P =	0.53	← Les	s death	ns in H	IFmrEF More d	leaths in HFmrB	EF →
Random effects REN	/L mo	del					

HFmrEF Vs HFrEF (B) HFmrEF Vs HFpEF (A) Risk ratio Risk ratio with 95% CI Study p-value Study with 95% CI p-value Proportion of males \$50% Proportion of males <50% 1.01 [0.91, 1.13] 0.825 Males >50% 10 0.87 [0.79, 0.96] 0.006 Males >50N Males <50% 1.00[0.99, 1.03] 0.626 Males \$50% 1.01 [0.98, 1.04] 0.442 Test of group differences: Q1(1) = 7.82, P = 0.01 Test of group differences: $Q_{\rm s}(1) = 0.00, P = 0.99$ Mean age S50 years Mean age ≤50 years 15 0.92[0.85, 0.99] 0.031 Mean age >50 years 1.01 [0.94, 1.09] 0.714 Mean age >50 years 14 Mean age ≤50 years 0.94[0.82, 1.07] 0.327 Mean age ≤50 years 1.13[0.99, 1.28] 0.052 Test of group differences: Q₁(1) = 0.06, P = 0.81 Test of group differences: Q_b(1) = 2.09, P = 0.15 Hospital vs outpatients Hospital vs outpatients Hospitalised 13 0 97 [0 94 1 011 0 131 Hospitalised 12 1.01[0.93, 1.08] 0.871 Outpatient 0.78 [0.65, 0.93] 0.006 Outpatient 3 1.10 [0.98, 1.25] 0.108 3 Test of group differences: Q₁(1) = 5.82, P = 0.02 Test of group differences: Q_b(1) = 1.64, P = 0.20 Single vs multi-cente Single vs multi-center Multi-center studies 0.98 [0.95, 1.01] 0.166 12 Multi-center studies 12 1.00[0.92, 1.07] 0.905 0.83 [0.69, 0.99] 0.037 Single center studies Sincle center studies 1.13 [1.03, 1.24] 0.008 3 Test of group differences: $Q_{1}(1) = 3.32$, P = 0.07Test of group differences: $Q_{\nu}(1) = 4.52$, P = 0.03Follow up period ≤2 years Follow up period ≤2 years 0.91 [0.78, 1.07] 0.278 Follow-up period s2 years 1.10 [0.98, 1.23] 0.105 Follow-up pariod ≤2 years Follow-up period >2 years 11 0.92[0.85, 1.00] 0.052 Follow-up period >2 years 10 1.00[0.93, 1.08] 0.931 Test of group differences: Q₁(1) = 0.01, P = 0.92 Test of group differences: Q₄(1) = 1.65, P = 0.20 0.92 [0.85, 0.99] 0.022 Overall 1.02 [0.96, 1.09] 0.525 Overall Heterogeneity: r² = 0.01, l² = 87.73%, H² = 8.15 Heterogeneity: 1² = 0.01, 1² = 82.80%, H² = 5.82 Test of $\theta_i = \theta_i$: Q(15) = 61.91, P = 0.00 Test of $\theta_1 = \theta_2$: O(14) = 76.73, P = 0.00 0.65 1.07 1.28 0.91 Random-effects REML model Random-effects REML model

Figure 3 Forest plots of sub-group analysis of long-term all-cause mortality in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF. HFmrEF, heart failure with mid-range (borderline) ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

Discussion

The salient features of our meta-analysis are (1) The risk of long-term all-cause mortality is reduced in patients with HFmrEF compared with HFrEF at 1, 2, and 3 years; beyond which the differences in mortality risk are insignificant; (2) the risk ratios for all-cause deaths between HFmrEF and HFrEF are different when accounting for gender disparity, while studies recruiting > 50% men show a higher risk of deaths in the HFrEF category compared with HFmrEF, the risk ratios are indifferent in studies recruiting higher proportion of women; (3) the risk of long-term all-cause mortality, cardiovascular and non-cardiovascular deaths is similar between patients with HFmrEF and HFpEF.

Our study is the largest meta-analysis of large-scale studies reporting long-term mortality outcomes in HFmrEF compared with HFrEF and HFpEF. The last meta-analysis on this topic included studies till end of April 2019 and had evaluated only the adjusted mortality ratios between these groups.²³ While two of the previous meta-analyses reported both short-term and long-term mortality ratios between the groups, only one meta-analysis reported the 1 year mortality ratios.^{22,24} The results of our study on the cumulative all-cause mortality outcomes between HFmrEF and HFrEF as well as HFpEF groups are consistent with the earlier meta-analyses.^{22,26} While HFmrEF bears a better long-term progno-

sis compared with HFrEF, the outcomes seem to be similar compared with HFpEF.

Our study, in addition, explores the annual mortality outcomes in the follow-up. Beyond 3 years, the risk differences seem to level out between HFmrEF and HFrEF. This observation could be due to either transition in LVEF from one group to the other in the follow-up, or inadequate power of the very long-term studies to detect differences in the deaths between the two groups. Transition of patients from one group to the other has not been reported uniformly in the registries. In a seminal study involving 4942 patients, amongst those patients with HFmrEF, 37% patients had worsened to HFrEF and 25% patients improved to HFpEF category. Also, 21% patients of HFpEF had progressive failing of LV function and shifted to HFmrEF category and 16% patients of HFrEF improved to the HFmrEF category.²⁷ This shows that HFmrEF is likely a heterogenous entity comprising patients with improved ejection fraction, stable left ventricular functions, and progressive LV dysfunction. Though LVEF helps to categorize these patients, the dynamic change in LVEF is an important consideration to keep in mind while interpreting the long-term outcomes.

Gender disparity between studies and its influence on the outcomes is revealed in our analysis. Studies with more proportions of women had comparable risk of deaths between HFmrEF and HFrEF, while those with more proportion of men had higher risk of deaths in HFrEF. Studies on gender dif. . .

Figure 4 Forest plots demonstrating annual all-cause deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF. HFmrEF, heart failure with mid-range (borderline) ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

(A)	HFm	nrEF	HF	EF		0 interestion		₁ (B)	HFm	IrEF	HF	pEF		Pick min	Weight
Study	Died	No	Died	No		with 95% CI	(%)	Study	Died	No	Died	No		with 95% CI	(%)
Year 1							1.07	Year 1							
Coles 2014	02	254	515	984		0.761.0.63.0.921	4.84	Coles 2014	92	254	532	1.247		0.89[0.74, 1.07]	4.92
Chioscel 201	168	2044	490	4 9 90		0.961073 102	4.93	Chloncel 201	168	2.044	92	1,370		1,21 [0.94, 1.54]	4.28
Gemez-Otem 2017	65	172	110	487		-1221092 161	4 94	Gomez-Otoro 2017	55	172	118	492		-1.2510.95. 1.65	3.90
Ch-1 2018 AD	88	205	490	1 121		0831088 101	4.78	Choi 2018 AD	88	295	144	469		0.9810.78 1.23	4.43
Cristole Encodere 2018	60	225	100	687		0231056 002	4.70	Guisado-Escadero 2018	58	225	305	1 208		0.91 [0.70 1.16]	4.22
Conside Capariano 2010		225	100	1004		0.51 [0.35, 0.32]	1 1 1	Lam 2018	17	250	44	628		0.83[0.48 1.42]	1.05
Cam 2010		239	133	1,000		0.52 [0.52, 0.65]	3.00	Canacethi 2020	83	148	248	619	_	128(103 150	4.77
Company 2020	- 43.04	140	139	240		0.81 [0.74, 1.13]	4.73	Heteroperator r ² = 0.01 l ²	= 48.67	5 H ² = 1	89			105(0.92, 1.3)	
newrogenery: 1 = 0.02,1	- 53,81	n, n = 2				0.64 [0.74, 0.95]	,	Text of 0 = 0 : 0(0) = 11 18	P=00	a	~~				
Heet of H = H; Q(0) = 13.50	, <i>P</i> = 0.0	2						1011010(- 0. 0(0) - 11.10							
Year 2								Year 2							
Color 2014		222	722	266		0951074 007	5.08	Colors 2014	144	200	770	1.009		0.961.0.84 1.101	5.49
1 2018	30	228	193	078		0811043 087	3.01	Lam 2018	30	226	80	494		0.8410.57, 1.251	2.87
China 2010	30	226	235	376		0011045 020	3.01	Shina 2019	40	200	79	417		1011071 141	324
Singu zuria	40	200	13	334		0.01[0.04, 120]	3.93	Gaogoothi 2020	101	130	309	658		123[103 145]	5.11
Carlapatri 2020		130	105	221		0.97 [0.81, 1.16]	4.67	Heteroperativ $r^2 = 0.01 I^2$	= 50.25	K H ² = 2	01			1031088 121	0.11
meserogeneity: 1 = 0.01,1	- 33.62	N, M = 3	,51			0.9610.12, 0.961	,	Test of B = B : O(3) = 5.99	P=0.11		~			1.00[0.00, 1.2.]	
Net of N = N; (N(3) = 3.31,	P=0.15							10110101-01.0(0)-0.00							
Year 3								Year 3							
Koh 2017	9.019	23 400	9.640	2 512		0351034 036	5.32	Koh 2017	9,019	23,402	6,507	6,708		0.58 [0.55, 0.58]	8.24
Gaosoviti 2020	231	404	\$67	112		0411037 046	5 16	Ganapathi 2020	231	401	119	207		1.0010.84. 1.19	5.05
Hetware about 2 = 0.01 12			59			0.9910.92 0.40		Heteropenety: $r^2 = 0.16$, r^2	- 97 44	5 H ² - 3	205	-		0751043 130	
Test of 0 = 0: 0(1) = 8.98	P = 0.00							Test of 0. = 0.: Q(1) = 39.00	P=00	0					
10.0.0 - 0.0(1) - 0.00															
Year 4								Year 4							
Pascual-Piga	128	332	775	1,575		0.6410.72, 0.99	4.97	Poscual-Figa	128	332	178	457	-0	0.99 [0.82, 1.20]	4.87
Ganapathi 2020	125	105	231	173	-	0.8510.82, 1.09	5.02	Ganapathi 2020	125	106	411	456	-8	1.14[0.99, 1.31]	5.47
Heterogeneity: $T^2 = 0.00, 1^2$	= 10.07	4. H ² = 1	.11			0.9010.80. 1.001		Heterogeneity: 1 ² = 0.00, 1 ²	= 25.02	5, H ² = 1	.33		-	1.08 [0.05, 1.24]	
Test of A = A: O(1) = 1.11.	P=0.29				•			Test of 0, = 0,: Q(1) = 1.33,	P=0.15				T		
Year 5								Year 5							
Coles 2014	241	105	1,052	427	1 🖷	0.98 [0.91, 1.06]	5.24	Coles 2014	241	106	1,222	557	-@-	1.01 [0.94, 1.09]	8.00
Bonau 2017	89	178	119	228		0.97 0.78, 1.22	4.68	Boneu 2017	88	176	264	614		1.12 [0.92, 1.36]	4.03
Shah 2017	2.487	798	13,847	4,551	i i	1.01 [0.98, 1.03]	5.32	Shah 2017	2,437	760	13,843	4,456	<u>i</u>	1.00 [0.98, 1.02]	5.24
Ganapathi 2020	135	95	254	150	-	0.8410.02. 1.07	5.03	Ganepathi 2020	135	95	453	414	-8	1.13 [0.99, 1.28]	5.69
Heteropeneity: 1 ⁴ = 0.00, 1 ⁴	= 0.01%	H ^T = 1.0	0			1.0010.88, 1.021		Heterogeneity: r ² = 0.00, I ²	= 34.17	%, H ² = 1	.52		•	1.02 [0.98, 1.07]	
Test of Q = Q; Q(3) = 1.55,	P = 0.67							Test of 0, = 0;: Q(3) = 4.51,	P=0.21						
Year 10								Year 10							
Vergaro 2019	166	457	631	908		0.65 [0.56, 0.75]	5.03	Vergaro 2019	168	457	144	485		1.18 [0.96, 1.41]	4.86
Farre 2017	221	283	1,023	1,209	-	0.96 0.86, 1.07	5.15	Fame 2017	221	283	444	400	-8-	0.83 [0.74, 0.94]	5.65
Heteropeneity: 1 ² = 0.07, 1 ²	- \$4 37	6. H ² - 1	7.75			0.7910.54, 1.18		Heterogeneity: r ² = 0.05, I ²	- 37.99	4. 11 - 3	33			0.96 [0.70, 1.35]	
Test of 0. = 0: Q(1) = 17.75	P=00	•						Test of 0, = 0;: G(1) = 8.33,	P = 0.00						
Overall					 	0.79 [0.69, 0.91]	1	Overall						1.00 [0.91, 1.09]	
Heterogeneity: $r^2 = 0.09$, I^2	= 98.41	%, H ² = 0	2.88		T I			Heterogeneity: r ² = 0.03, l ²	= 94.95	4, H ² = 1	9.82				
Test of 8. = 8; Q(20) = 668	1.65, P =	0.00						Test of 0, = 0;: Q(20) = 139	7.30, P =	0.00					
Test of annua differences	10-		- 0.00					Test of group differences: C	2.(5) = 2	10.P=0	84				
rest of group a terances: C	-1/0) = 1	00.00, P :	- 5.05	-										-	
0			-101	s deaths in l	.5 1 Heatin provide	1.5 Riski HEIDEE		Rendom efforts REM mode	d		404	s cours i	n Hfm EF nove deaths	in Hifm (CF	
Rancom-effects REML mode	66				10000										

ferences in incidence and prognosis of heart failure show higher risk of HFrEF, incident heart failure and deaths in men compared with higher incidence of HFpEF amongst women.²⁸ Hospitalization is an important event in the natural history of HF that portends poor prognosis.²⁹ In our analysis, the studies including only outpatients had reported lesser all-cause mortality rates ranging from 7.6% to 28% in HFmrEF group compared with mortality rates ranging from 18% to 75% in the studies including only hospitalized patients. Predictably, our subgroup analysis showed a significantly reduced deaths in the HFmrEF compared with HFrEF only amongst the studies reporting outpatients.

An individual patient data meta-analysis showed no differences in the risks of all-cause mortality as well as cardiovascular deaths at LVEF \geq 40%.²⁶ Our observation also shows no differences in absolute mortality, cardiovascular, non-cardiovascular and sudden cardiac deaths, between the HFmrEF and HFpEF groups. Thus, this group is a large cluster of heart failure patients, wherein LVEF fails to dictate prognosis. This underlines the need to look for additional non-cardiac and cardiac prognostic indicators like associated co-morbidities, cardiac MRI, and arrhythmia burden. Cardiac specific investigations need to be considered beyond the conventional echocardiogram in this subset. Recent large-scale studies have shown that cardiac MRI could identify subtle myocardial abnormalities in this subset that may portend a poor prognosis both in terms of worsening myocardial dysfunction and increase in risk of arrhythmias.³⁰ Figure 5 Forest plots demonstrating cardiovascular deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF. HFmrEF, heart failure with mid-range (borderline) ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

(A)	HFm	nrEF	HFr	EF		Risk ratio	Weight
Study	Died	No	Died	No		ith 95% CI	(%)
Bonsu 2017	86	179	116	229	0.97	[0.77, 1.21]	12.27
Chioncel 2017	85	2,127	257	5,203	0.82	[0.64, 1.04]	12.00
Farre 2017	100	404	492	1,740	0.90	[0.74, 1.09]	13.08
Gomez-Olero 2017	36	191	89	494	1.04	[0.73, 1.48]	9.43
Pascual-Figal 2017	93	367	621	1,730		[0.63, 0.93]	13.04
Hamatani 2018	26	292	101	759		[0.46, 1.05]	8.32
Shiga 2019	21	227	41	371	0.85	[0.52, 1.41]	6.78
Vergaro 2019	74	549	415	1,124		[0.35, 0.55]	12.25
Liu 2021	128	823	204	863		[0.57, 0.86]	12.84
Overall					0.77	[0.65, 0.92]	
Heterogeneity: τ ² = 0	.05, l ² :	= 76.019	6, H ² =	4.17			
Test of $\theta_i = \theta_j$: Q(8) =	33.17,	P = 0.00)				
Test of θ = 0: z = -2.9	93, P =	0.00					
Random-effects REMI	_ mode	I		-less deal	.5 1 hhs in HFmrEF more deaths in HF	mrEF →	
(B)	HEn	nrEE	не	DEE	c	liek ratio	Weight
Study	Died	No	Died	No	wit	th 95% CI	(%)
Bonsu 2017							
	86	179	252	626		[0.92, 1.38]	25.55
Chioncel 2017	86 85	179 2,127	252 43	626 1,419	1.13	[0.92, 1.38] [0.91, 1.87]	25.55 8.06
Chioncel 2017 Farre 2017	85 85 100	179 2,127 404	252 43 188	626 1,419 656	1.13 1.31 0.89	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11]	25.55 8.06 22.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017	85 85 100 36	179 2,127 404 191	252 43 188 94	626 1,419 656 516	1.13 1.31 0.89 1.03	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46]	25.55 8.06 22.47 8.43
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017	86 85 100 36 93	179 2,127 404 191 367	252 43 188 94 110	626 1,419 656 516 525	1.13 1.31 0.89 1.03 1.17	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50]	25.55 8.06 22.47 8.43 16.96
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018	86 85 100 36 93 26	179 2,127 404 191 367 292	252 43 188 94 110 42	626 1,419 656 516 525 572	1.13 1.31 0.89 1.03 1.17 1.20	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91]	25.55 8.06 22.47 8.43 16.96 4.75
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019	86 85 100 36 93 26 21	179 2,127 404 191 367 292 227	252 43 188 94 110 42 46	626 1,419 656 516 525 572 450	1.13 1.31 0.89 1.03 1.17 1.20 0.91	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50]	25.55 8.06 22.47 8.43 16.96 4.75 4.31
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019	86 85 100 36 93 26 21 74	179 2,127 404 191 367 292 227 549	252 43 188 94 110 42 46 54	626 1,419 656 516 525 572 450 575	1.13 1.31 0.89 1.03 1.17 1.20 0.91 1.38	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019 Overall	86 85 100 36 93 26 21 74	179 2,127 404 191 367 292 227 549	252 43 188 94 110 42 46 54	626 1,419 656 516 525 572 450 575	1.13 1.31 0.89 1.03 1.17 1.20 0.91 1.38 1.10	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93] [0.99, 1.21]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019 Overall Heterogeneity: I ² = 6	86 85 100 36 93 26 21 74 .02%, I	179 2,127 404 191 367 292 227 549 H ² = 1.0	252 43 188 94 110 42 46 54	626 1,419 656 516 525 572 450 575	1.13 1.31 0.89 1.03 1.17 1.20 0.91 1.38 1.10	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93] [0.99, 1.21]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019 Overall Heterogeneity: $I^2 = 6$ Test of $\theta_i = \theta_i$: Q(7) =	86 85 100 36 93 26 21 74 .02%, I	179 2,127 404 191 367 292 227 549 $H^2 = 1.0$ P = 0.38	252 43 188 94 110 42 46 54 6	626 1,419 656 516 525 572 450 575	1.13 1.31 0.89 1.03 1.17 1.20 0.91 1.38 1.10	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93] [0.99, 1.21]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019 Overall Heterogeneity: $I^2 = 6$ Test of $\theta_i = \theta_i$: $Q(7) =$ Test of $\theta = 0$: $z = 1.74$	86 85 100 36 93 26 21 74 .02%, I 7.45, J 4, P = (179 2,127 404 191 367 292 227 549 $H^2 = 1.0$ P = 0.38 0.08	252 43 188 94 110 42 46 54 6	626 1,419 656 516 525 572 450 575	1.13 1.31 0.89 1.03 1.17 1.20 0.91 1.38 1.10	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93] [0.99, 1.21]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47
Chioncel 2017 Farre 2017 Gomez-Otero 2017 Pascual-Figal 2017 Hamatani 2018 Shiga 2019 Vergaro 2019 Overall Heterogeneity: $I^2 = 6$ Test of $\theta_i = \theta_i$: Q(7) = Test of $\theta = 0$: z = 1.74	86 85 100 36 93 26 21 74 .02%, I 7,45, <i>I</i> 4, <i>P</i> = (179 2,127 404 191 367 292 227 549 $H^2 = 1.0$ P = 0.38 0.08	252 43 188 94 110 42 46 54 6	626 1,419 656 516 525 572 450 575	1.13 1.31 1.31 1.31 1.31 1.33 1.03 1.17 1.20 0.91 1.38 1.10 1.10	[0.92, 1.38] [0.91, 1.87] [0.72, 1.11] [0.72, 1.46] [0.91, 1.50] [0.75, 1.91] [0.56, 1.50] [0.99, 1.93] [0.99, 1.21]	25.55 8.06 22.47 8.43 16.96 4.75 4.31 9.47

Limitations

(1) In spite of application of strict eligibility criteria, our meta-analysis does bear a high level of heterogeneity between the included studies. This heterogeneity was adequately addressed statistically with appropriate sensitivity, subgroup and meta-regression analysis. The results seem to be unaffected by any of the included studies. (2) The lack of a standard reporting protocol of long-term outcomes in registries was evident during our systematic review, such as variable period of follow-up; gender disparity; variable age groups; variable outcomes in single and multi-centre studies; inclusion of both hospitalized and outpatients in a few studies; inclusion of both de novo and chronic heart failure patients in a few registers; and representation of more valvular heart diseases and myocardial infarction in a few registries. We have attempted to address this heterogeneity arising due to clinical variables in our subgroup analysis. (3) Medical therapy has improved enormously with regards to heart failure. However, due to considerable heterogeneity in the reporting of medical therapy in the included studies, we could not address this in the subgroup analysis. (4) It is possible that, the recruited studies did not have adequate power to detect significant differences in risk-ratios in heart failure deaths and very long-term (beyond 3 years) deaths between HFmrEF and HFrEF groups. Similarly, the single-centre studies may not have sufficient power to detect enough deaths in the HFpEF group.

Future directives

(1) Adoption of a standard reporting guideline on long-term outcomes with respect to the clinically relevant confounders could reduce the level of heterogeneity between studies; (2) transition in LVEF needs to be considered while analysing the outcomes in chronic heart failure; (3) additional risk-stratification tools should be aggressively sought to understand better the similarities and differences between HFmrEF and HFpEF.

Conclusions

Our meta-analysis concludes that risk of long-term all-cause mortality is less in patients with HFmrEF compared with HFrEF till 3 years; beyond which the differences in mortality risk were insignificant, for which transition in LVEF could play an important role. The insignificant differences in the risk-ratio between HFmrEF and HFrEF while considering studies representing greater proportion of women, suggests that gender disparity may play a divisive role in determining outcomes. The differences in risk of long-term all-cause mortality were comparable between patients with HFmrEF compared with HFpEF, thus suggesting the need to explore the mortality risks with tools other than LVEF.

Acknowledgements

We acknowledge the support extended by Murray Turner, liaison librarian for Faculty of Health, Library, University of Canberra. Dr Sanders is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia.

Conflicts of interest

Dr Sanders reports having served on the advisory board of Medtronic, Abbott Medical, Boston Scientific, CathRx and PaceMate. Dr Sanders reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic, Abbott Medical, and Boston Scientific. Dr Sanders reports that the University of Adelaide has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, BD, and Microport. All other authors have no disclosures. Dr Pathak reports having served on the advisory board of Medtronic, Abbott Medical, Boston Scientific. Dr Pathak reports that Canberra Heart Rhythm Foundation has received on his behalf lecture and/or consulting fees from Medtronic, Abbott Medical, Boston Scientific and Biotronik. Dr Pathak reports that Canberra Heart Rhythm Foundation has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, and Biotronik. Dr Pathak reports that Canberra Heart Rhythm Foundation has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, and Biotronik.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1: Forest plots demonstrating non-cardiovascular deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF; HFmrEF- heart failure with mid-range (borderline) ejection fraction, HFrEF- heart failure with reduced ejection fraction, HFpEF- heart failure with preserved ejection fraction.

Figure S2: Forest plots demonstrating heart failure deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF; HFmrEF-heart failure with mid-range (borderline) ejection fraction, HFrEF- heart failure with reduced ejection fraction, HFpEF-heart failure with preserved ejection fraction.

Figure S3: Forest plots demonstrating sudden cardiac deaths in (A) HFmrEF and HFrEF, and (B) HFmrEF and HFpEF; HFmrEF- heart failure with mid-range (borderline) ejection fraction, HFrEF- heart failure with reduced ejection fraction, HFpEF- heart failure with preserved ejection fraction.

 Table S1: Enumeration of the detailed search strategy.

 Table S2: Newcastle-Ottawa quality assessment scale (NOS)

 for cohort studies.

 Table S3: The distribution of patient characteristics between

 the three groups.

References

 Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. *Circulation*. 2007; **115**: 1563–1570.

 Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Candesartan in heart failure reduction in mortality I. influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation*. 2005; **112**: 3738–3744.

- Srivastava PK, Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range ejection fraction. *Curr Heart Fail Rep.* 2020; 17: 1–8.
- Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Clinical characteristics and prognosis of patients admitted for heart failure: A 5-year retrospective study of African patients. *Int J Cardiol.* 2017; 238: 128–135.
- Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. *Am Heart J*. 2014; 168: 721–730.
- Coles AH, Fisher K, Darling C, Yarzebski J, McManus DD, Gore JM, Lessard D, Goldberg RJ. Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. *Am J Cardiol.* 2014; 114: 862–868.
- 7. Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, de Filippi CR, Enserro D, Blaha MJ, Cushman M, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Brouwers FP, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL Jr, Levy D, Herrington DM, van Gilst WH, Bertoni AG, Larson MG, de Boer RA, Gottdiener JS, Shah SJ, Ho JE. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018; 20: 651–659.
- Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017; 19: 1574–1585.
- Choi KH, Lee GY, Choi JO, Jeon ES, Lee HY, Cho HJ, Lee SE, Kim MS, Kim JJ, Hwang KK, Chae SC, Baek SH, Kang SM, Choi DJ, Yoo BS, Kim KH, Park HY, Cho MC, Oh BH. Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. *Heart*. 2018; **104**: 525–532.
- 10. Farre N, Lupon J, Roig E, Gonzalez-Costello J, Vila J, Perez S, de Antonio M, Sole-Gonzalez E, Sanchez-Enrique C, Moliner P, Ruiz S, Enjuanes C, Mirabet S, Bayes-Genis A, Comin-Colet J, Investigators G. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: A multicentre prospective observational study in Catalonia (Spain). *BMJ Open.* 2017; 7: e018719.

- Ganapathi S, Jeemon P, Krishnasankar R, Kochumoni R, Vineeth P, Mohanan Nair KK, Valaparambil AK, Harikrishnan S. Early and long-term outcomes of decompensated heart failure patients in a tertiary-care Centre in India. *ESC Heart Fail.* 2020; 7: 467–473.
- 12. Gomez-Otero I, Ferrero-Gregori A, Varela Roman A, Seijas Amigo J, Pascual-Figal DA, Delgado Jimenez J, Alvarez-Garcia J, Fernandez-Aviles F, Worner Diz F, Alonso-Pulpon L, Cinca J, Gonzalez-Juanatey JR, Red Espanola de Insuficiencia Cardiaca r. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. *Rev Esp Cardiol* (*Engl Ed*). 2017; **70**: 338–346.
- Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas O, Conde-Martel A, Arias-Jimenez JL, Llacer-Iborra P, Davila-Ramos MF, Cabanes-Hernandez Y, Manzano L, Montero-Perez-Barquero M, group Ri. Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: Findings from the RICA registry. Int J Cardiol. 2018; 255: 124–128.
- 14. Hamatani Y, Nagai T, Shiraishi Y, Kohsaka S, Nakai M, Nishimura K, Kohno T, Nagatomo Y, Asaumi Y, Goda A, Mizuno A, Yasuda S, Ogawa H, Yoshikawa T, Anzai T. Investigators for the WETNCP. Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. Am J Cardiol. 2018; 121: 731–738.
- Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CSP, Lund LH. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. *Eur J Heart Fail*. 2017; 19: 1624–1634.
- Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Cameron VA, Poppe K, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. *Eur Heart J.* 2018; **39**: 1770–1780.
- Liu D, Hu K, Lau K, Kiwitz T, Robitzkat K, Hammel C, Lengenfelder BD, Ertl G, Frantz S, Nordbeck P. Impact of diastolic dysfunction on outcome in heart failure patients with mid-range or reduced ejection fraction. *ESC Heart Fail*. 2021; 8: 2802–2815.
- Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J, Gimeno-Blanes JR, Worner-Diz F, Bardaji A, Alonso-Pulpon L, Gonzalez-Juanatey JR, Cinca J. Music, groups RIr. Mid-range left ventricular ejection fraction: Clinical profile and cause of death

in ambulatory patients with chronic heart failure. *Int J Cardiol.* 2017; **240**: 265–270.

- Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. *J Am Coll Cardiol.* 2017; **70**: 2476–2486.
- 20. Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, Oka T, Tanaka H, Murasaki S, Yamauchi T, Katoh J, Hattori H, Kikuchi N, Watanabe E, Yamada Y, Haruki S, Kogure T, Suzuki T, Uetsuka Y, Hagiwara N, Investigators H-HI. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. *ESC Heart Fail.* 2019; 6: 475–486.
- 21. Vergaro G, Ghionzoli N, Innocenti L, Taddei C, Giannoni A, Valleggi A, Borrelli C, Senni M, Passino C, Emdin M. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. J Am Heart Assoc. 2019; 8: e013441.
- Altaie S, Khalife W. The prognosis of mid-range ejection fraction heart failure: A systematic review and metaanalysis. ESC Heart Fail. 2018; 5: 1008–1016.
- Guo P, Dai JF, Feng C, Chen ST, Feng JP. Special prognostic phenomenon for patients with mid-range ejection fraction heart failure: A systematic review and meta-analysis. *Chin Med J (Engl)*. 2020; 133: 452–461.
- 24. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: A systematic review and metaanalysis. ESC Heart Fail. 2018; 5: 685–694.
- 25. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015; **4**: 1.
- 26. Meta-analysis Global Group in Chronic Heart F. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. *Eur Heart J.* 2012; **33**: 1750–1757.
- Savarese G, Vedin O, D'Amario D, Uijl A, Dahlstrom U, Rosano G, Lam CSP, Lund LH. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. *JACC Heart Fail*. 2019; 7: 306–317.
- Taylor CJ, Ordonez-Mena JM, Jones NR, Roalfe AK, Lay-Flurrie S, Marshall T, Hobbs FDR. National trends in heart failure mortality in men and women, United Kingdom, 2000-2017. Eur J Heart Fail. 2021; 23: 3–12.

- 29. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the atherosclerosis risk in communities study). *Am J Cardiol*. 2008; **101**: 1016–1022.
- Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, Dallaglio PD, Comin-Colet J, Anguera I, Miller CA, Schmitt M. Improved risk stratification for ventricular arrhythmias

and sudden death in patients with nonischemic dilated cardiomyopathy. *J Am Coll Cardiol*. 2021; **77**: 2890–2905.